Top

Published in:

01-07-2019 | Radiotherapy | RADIOTHERAPY

Concomitant radiotherapy and TKI in metastatic EGFR- or ALK-mutated non-small cell lung cancer: a multicentric analysis on behalf of AIRO lung cancer study group

Authors: Paolo Borghetti, Marco Lorenzo Bonù, Rachele Giubbolini, Niccolo’ Giaj Levra, Rosario Mazzola, Marco Perna, Luca Visani, Fiammetta Meacci, Maria Taraborrelli, Luca Triggiani, Davide Franceschini, Carlo Greco, Alessio Bruni, Stefano Maria Magrini, Vieri Scotti

Published in: La radiologia medica | Issue 7/2019

Abstract

Purpose

To investigate the role of radiotherapy (RT) in the management of EGFR- or ALK-mutated metastatic non-small cell lung cancer (NSCLC) treated with TKI.

Materials and methods

Clinical data of 106 patients (pts) from five Institutions treated with RT concomitant to TKI were retrospectively revised. Overall survival (OS) and toxicities were analyzed as endpoints of the study.

Results

Median age of pts was 65 years. TKIs were given for EGFR (81%)- or ALK (19%)-mutated metastatic NSCLC. Stereotactic RT (SRT) was delivered to 49 pts (46%). Patients with four or less metastasis were defined as oligometastatic/oligoprogressive (OM/OP); sites of RT were brain, bone, lung or others in 46%, 27%, 14% and 13%, respectively. Median OS was 23 months. At univariate analysis SRT, ECOG PS 0–1, OM/OP disease, lung sites and a TKI duration longer than median favorably affected OS (all p < 0.001). Multivariate analysis confirmed SRT (HR 0.355, CI 95% 0.212–0.595; p < 0.001) and median duration of TKI > 14 months (HR 0.17, 95% CI 0.10–0.30; p < 0.001) as independent factors related to better OS. Toxicities were rare.

Conclusions

SRT seems to positively affect OS with limited toxicity in selected patients.

Burotto M, Manasanch EE, Wilkerson J, Fojo T (2015) Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials. Oncologist 20(4):400–410. https://doi.org/10.1634/theoncologist.2014-0154 CrossRefPubMedPubMedCentral

Masters GA, Temin S, Azzoli CG, Giaccone G, Baker S, Brahmer JR et al (2015) Systemic therapy for stage IV non-small-cell lung cancer: american society of clinical oncology clinical practice guideline update. J Clin Oncol 33(30):3488–3515. https://doi.org/10.1200/JCO.2015.62.1342 CrossRefPubMedPubMedCentral

Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T et al (2017) Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet 390(10089):29–39. https://doi.org/10.1016/S0140-6736(17)30565-2 CrossRefPubMed

Lee CK, Brown C, Gralla RJ, Hirsh V, Thongprasert S, Tsai CM et al (2013) Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst 105(9):595–605. https://doi.org/10.1093/jnci/djt072 CrossRefPubMed

Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13(3):239–246. https://doi.org/10.1016/S1470-2045(11)70393-X CrossRefPubMed

Paz-Ares L, Tan EH, O’Byrne K, Zhang L, Hirsh V, Boyer M et al (2017) Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Ann Oncol 28(2):270–277. https://doi.org/10.1093/annonc/mdw611 CrossRefPubMedPubMedCentral

Parikh RB, Cronin AM, Kozono DE, Oxnard GR, Mak RH, Jackman DM et al (2014) Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer. Int J Radiat Oncol Biol Phys 89(4):880–887. https://doi.org/10.1016/j.ijrobp.2014.04.007 CrossRefPubMed

Rusthoven KE, Hammerman SF, Kavanagh BD, Birtwhistle MJ, Stares M, Camidge DR (2009) Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis. Acta Oncol 48(4):578–583. https://doi.org/10.1080/02841860802662722 CrossRefPubMed

Yano T, Okamoto T, Haro A, Fukuyama S, Yoshida T, Kohno M et al (2013) Local treatment of oligometastatic recurrence in patients with resected non-small cell lung cancer. Lung Cancer 82(3):431–435. https://doi.org/10.1016/j.lungcan.2013.08.006 CrossRefPubMed

10.

Torok J, Kelsey CR, Salama JK (2013) Patterns of distant metastases in surgically managed early stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys 87:S528–S529CrossRef

11.

Niibe Y, Hayakawa K (2010) Oligometastases and oligo-recurrence: the new era of cancer therapy. Jpn J Clin Oncol 40(2):107–111. https://doi.org/10.1093/jjco/hyp167 CrossRefPubMedPubMedCentral

12.

De Ruysscher D, Wanders R, van Baardwijk A, Dingemans AM, Reymen B, Houben R et al (2012) Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450). J Thorac Oncol 7(10):1547–1555. https://doi.org/10.1097/jto.0b013e318262caf6 CrossRefPubMed

13.

Griffioen GH, Toguri D, Dahele M, Warner A, de Haan PF, Rodrigues GB et al (2013) Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors. Lung Cancer 82(1):95–102. https://doi.org/10.1016/j.lungcan.2013.07.023 CrossRefPubMed

14.

Cheruvu P, Metcalfe SK, Metcalfe J, Chen Y, Okunieff P, Milano MT (2011) Comparison of outcomes in patients with stage III versus limited stage IV non-small cell lung cancer. Radiat Oncol 6:80. https://doi.org/10.1186/1748-717X-6-80 CrossRefPubMedPubMedCentral

15.

Gomez DR, Blumenschein GR, Lee JJ, Hernandez M, Ye R, Camidge DR et al (2016) Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol 17(12):1672–1682. https://doi.org/10.1016/S1470-2045(16)30532-0 CrossRefPubMedPubMedCentral

16.

Zhuang H, Wang J, Zhao L, Yuan Z, Wang P (2013) The theoretical foundation and research progress for WBRT combined with erlotinib for the treatment of multiple brain metastases in patients with lung adenocarcinoma. Int J Cancer 133(10):2277–2283. https://doi.org/10.1002/ijc.28290 CrossRefPubMed

17.

Chinnaiyan P, Huang S, Vallabhaneni G, Armstrong E, Varambally S, Tomlins SA et al (2005) Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 65(8):3328–3335. https://doi.org/10.1158/0008-5472.CAN-04-3547 CrossRefPubMed

18.

Mehta N, Mauer AM, Hellman S, Haraf DJ, Cohen EE, Vokes EE et al (2004) Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment. Int J Oncol 25(6):1677–1683PubMed

19.

NCCN (2018) Guidelines non small cell lung cancer (Version 1.2018); https://www.nccn.org/. Accessed Apr 2018

20.

Novello S, Barlesi F, Califano R, Cufer T, Ekman S, Levra MG et al (2016) Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 27(suppl 5):v1–v27. https://doi.org/10.1093/annonc/mdw326 CrossRefPubMed

21.

Gan GN, Weickhardt AJ, Scheier B, Doebele RC, Gaspar LE, Kavanagh BD et al (2014) Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib. Int J Radiat Oncol Biol Phys 88(4):892–898. https://doi.org/10.1016/j.ijrobp.2013.11.010 CrossRefPubMedPubMedCentral

22.

Palma DA, Olson RA, Harrow S, Gaede S, Louie AV, Haasbeek C et al (2018) Stereotactic ablative radiation therapy for the comprehensive treatment of oligometastatic tumors (SABR-COMET): results of a randomized trial. Int J Radiat Oncol Biol Phys 102(3):S3–S4CrossRef

23.

Kroeze SG, Fritz C, Hoyer M, Lo SS, Ricardi U, Sahgal A et al (2017) Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: a systematic review. Cancer Treat Rev 53:25–37. https://doi.org/10.1016/j.ctrv.2016.11.013 CrossRefPubMed

Title: Concomitant radiotherapy and TKI in metastatic EGFR- or ALK-mutated non-small cell lung cancer: a multicentric analysis on behalf of AIRO lung cancer study group
Authors: Paolo Borghetti
Marco Lorenzo Bonù
Rachele Giubbolini
Niccolo’ Giaj Levra
Rosario Mazzola
Marco Perna
Luca Visani
Fiammetta Meacci
Maria Taraborrelli
Luca Triggiani
Davide Franceschini
Carlo Greco
Alessio Bruni
Stefano Maria Magrini
Vieri Scotti
Publication date: 01-07-2019
Publisher: Springer Milan
Keywords: Radiotherapy
NSCLC
NSCLC
Tyrosine Kinase Inhibitors
Tyrosine Kinase Inhibitors
Published in: La radiologia medica / Issue 7/2019
Print ISSN: 0033-8362
Electronic ISSN: 1826-6983
DOI: https://doi.org/10.1007/s11547-019-00999-w

At a glance: The STEP trials

Springer Medicine

Concomitant radiotherapy and TKI in metastatic EGFR- or ALK-mutated non-small cell lung cancer: a multicentric analysis on behalf of AIRO lung cancer study group

Abstract

Purpose

Materials and methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Materials and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2019

MRI diagnosis of suprascapular neuropathy using spinoglenoid notch distension

MR arthrographic evaluation of the association between anterolateral soft tissue impingement and osteochondral lesion of the tibiotalar joint

In-stent restenosis associated with dual-layer Roadsaver carotid artery stent: a retrospective single-center study

CT findings after pelvic exenteration: review of normal appearances and most common complications

Value of structured reporting in neuromuscular disorders

Safety and efficacy of transcatheter embolization in patients with massive hemoptysis due to intercostal pulmonary venous shunts